概括
尼托普鲁西德和普拉佐辛在心力衰竭患者中同样降低了血压,并改善了心脏功能. 普拉佐辛表现出持续的效果,使其适合长期的血管扩张疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性心力衰竭带来了重大的治疗挑战.
- 血管扩张剂对于治疗心力衰竭至关重要.
- 尼托普鲁西德和普拉佐辛是具有明显临床应用的强效血管扩张剂.
研究的目的:
- 为了比较尼托普鲁西德和普拉佐辛的急性心脏循环效应.
- 为了评估它们在耐火性充血性心力衰竭患者中的有效性.
- 为了确定普拉佐辛是否适合长期血管扩张疗法.
主要方法:
- 一项涉及11名患有耐火性充血性心力衰竭的慢性冠心病患者的比较研究.
- 测量了血液动力学参数,包括全身动脉压,心率,左心室填充压力和心脏指数.
- 评估了全身血管阻力,前臂血管阻力 (FVR) 和前臂静脉度 (FVT).
主要成果:
- 尼托普鲁西德和普拉佐辛都同样降低了全身动脉压和左心室填充压,同时增加了心脏指数.
- 心肌氧消耗指数和心脏效率同样被这两种药物提高.
- 尼特罗普鲁西德和普拉佐辛在总系统性血管抵抗,FVR和FVT方面表现出相似的降低,表明平衡的动脉静脉放松.
- 普拉佐辛表现出长达六个小时的持续作用,症状有所改善.
结论:
- 尼托普鲁西德和普拉佐辛在患有严重心力衰竭的患者中表现出类似的急性血液动力学效应.
- 普拉佐辛的持续作用和症状改善表明其优越性对长期口服血管扩张剂治疗在门诊性心力衰竭.
- 口服普拉佐辛可以将医院内尼托普鲁塞德治疗的好处扩展到门诊机构.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
相关概念视频
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...